How did we get here?
Jorge Reyes, Evelyn Hsu – 25 April 2022
Jorge Reyes, Evelyn Hsu – 25 April 2022
Stefano Ciardullo, Marco Carbone, Pietro Invernizzi, Gianluca Perseghin – 25 April 2022 – Recently, an expert panel proposed diagnostic criteria for metabolic dysfunction–associated fatty liver disease (MAFLD) in the pediatric population. The aim of this study was to evaluate the prevalence of MAFLD among US adolescents and to investigate whether the new MAFLD definition is able to identify individuals with more advanced liver disease.
Robert A. Fisher – 25 April 2022
Manhal Izzy, Hilary M. DuBrock – 25 April 2022
AASLD created a variety of resources to help hepatologists and liver patients navigate COVID-19.
This is the first AASLD Practice Guidance on the management of malnutrition, frailty, and sarcopenia in patients with cirrhosis
Liver Transplantation (LT) is the treatment of choice for patients with decompensated cirrhosis, acute liver failure, small hepatocellular carcinomas (HCCs), or acute liver failure.
Access to liver transplants (LT) has profoundly altered the management of advanced liver disease.
Hepatocellular Carcinoma (HCC) is now the fifth-most common cancer in the world and the third cause of cancer-related mortality as estimated by the World Health Organization.
This AASLD 2018 Hepatitis B Guidance is intended to complement the AASLD 2016 Practice Guidelines for Treatment of Chronic Hepatitis B1 and update the previous hepatitis B virus (HBV) guidelines from 2009.